JB Chemicals & Pharmaceuticals Limited
J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage … Read more
JB Chemicals & Pharmaceuticals Limited (JBCHEPHARM) - Net Assets
Latest net assets as of September 2025: ₹38.06 Billion INR
Based on the latest financial reports, JB Chemicals & Pharmaceuticals Limited (JBCHEPHARM) has net assets worth ₹38.06 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹47.12 Billion) and total liabilities (₹9.07 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹38.06 Billion |
| % of Total Assets | 80.76% |
| Annual Growth Rate | 13.27% |
| 5-Year Change | 89.33% |
| 10-Year Change | 213.45% |
| Growth Volatility | 11.14 |
JB Chemicals & Pharmaceuticals Limited - Net Assets Trend (2005–2025)
This chart illustrates how JB Chemicals & Pharmaceuticals Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for JB Chemicals & Pharmaceuticals Limited (2005–2025)
The table below shows the annual net assets of JB Chemicals & Pharmaceuticals Limited from 2005 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹34.33 Billion | +17.45% |
| 2024-03-31 | ₹29.23 Billion | +17.86% |
| 2023-03-31 | ₹24.80 Billion | +15.98% |
| 2022-03-31 | ₹21.39 Billion | +17.93% |
| 2021-03-31 | ₹18.13 Billion | +26.11% |
| 2020-03-31 | ₹14.38 Billion | -3.03% |
| 2019-03-31 | ₹14.83 Billion | +2.67% |
| 2018-03-31 | ₹14.44 Billion | +5.75% |
| 2017-03-31 | ₹13.66 Billion | +24.70% |
| 2016-03-31 | ₹10.95 Billion | +10.10% |
| 2015-03-31 | ₹9.95 Billion | -4.60% |
| 2014-03-31 | ₹10.43 Billion | +2.21% |
| 2013-03-31 | ₹10.20 Billion | +5.19% |
| 2012-03-31 | ₹9.70 Billion | +40.26% |
| 2011-03-31 | ₹6.92 Billion | +21.73% |
| 2010-03-31 | ₹5.68 Billion | +21.16% |
| 2009-03-31 | ₹4.69 Billion | +3.50% |
| 2008-03-31 | ₹4.53 Billion | +8.26% |
| 2007-03-31 | ₹4.18 Billion | +26.66% |
| 2006-03-31 | ₹3.30 Billion | +16.26% |
| 2005-03-31 | ₹2.84 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to JB Chemicals & Pharmaceuticals Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2930689700000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹29.31 Billion | 85.36% |
| Common Stock | ₹155.70 Million | 0.45% |
| Other Comprehensive Income | ₹3.23 Billion | 9.40% |
| Other Components | ₹1.64 Billion | 4.79% |
| Total Equity | ₹34.33 Billion | 100.00% |
JB Chemicals & Pharmaceuticals Limited Competitors by Market Cap
The table below lists competitors of JB Chemicals & Pharmaceuticals Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Photronics Inc
NASDAQ:PLAB
|
$1.93 Billion |
|
Joulwatt Technology Co. Ltd. A
SHG:688141
|
$1.93 Billion |
|
Reliance Worldwide Corporation Limited
PINK:RLLWF
|
$1.93 Billion |
|
ePlus inc
NASDAQ:PLUS
|
$1.94 Billion |
|
Disc Medicine Inc.
NASDAQ:IRON
|
$1.93 Billion |
|
Changzhou Fusion New Material Co. Ltd. A
SHG:688503
|
$1.93 Billion |
|
Dynex Capital Inc
NYSE:DX
|
$1.93 Billion |
|
Aecc Aero Engine Control Co Ltd
SHE:000738
|
$1.93 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in JB Chemicals & Pharmaceuticals Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 29,233,300,000 to 34,333,200,000, a change of 5,099,900,000 (17.4%).
- Net income of 6,595,800,000 contributed positively to equity growth.
- Dividend payments of 2,370,400,000 reduced retained earnings.
- Share repurchases of 240,027,000 reduced equity.
- New share issuances of 240,000,000 increased equity.
- Other comprehensive income increased equity by 1,958,680,000.
- Other factors decreased equity by 1,084,153,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹6.60 Billion | +19.21% |
| Dividends Paid | ₹2.37 Billion | -6.9% |
| Share Repurchases | ₹240.03 Million | -0.7% |
| Share Issuances | ₹240.00 Million | +0.7% |
| Other Comprehensive Income | ₹1.96 Billion | +5.7% |
| Other Changes | ₹-1.08 Billion | -3.16% |
| Total Change | ₹- | 17.45% |
Book Value vs Market Value Analysis
This analysis compares JB Chemicals & Pharmaceuticals Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 9.73x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 59.64x to 9.73x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-03-31 | ₹35.28 | ₹2104.00 | x |
| 2006-03-31 | ₹41.02 | ₹2104.00 | x |
| 2007-03-31 | ₹49.69 | ₹2104.00 | x |
| 2008-03-31 | ₹53.72 | ₹2104.00 | x |
| 2009-03-31 | ₹55.60 | ₹2104.00 | x |
| 2010-03-31 | ₹67.37 | ₹2104.00 | x |
| 2011-03-31 | ₹81.69 | ₹2104.00 | x |
| 2012-03-31 | ₹114.62 | ₹2104.00 | x |
| 2013-03-31 | ₹120.44 | ₹2104.00 | x |
| 2014-03-31 | ₹123.04 | ₹2104.00 | x |
| 2015-03-31 | ₹117.31 | ₹2104.00 | x |
| 2016-03-31 | ₹128.95 | ₹2104.00 | x |
| 2017-03-31 | ₹160.77 | ₹2104.00 | x |
| 2018-03-31 | ₹171.68 | ₹2104.00 | x |
| 2019-03-31 | ₹180.08 | ₹2104.00 | x |
| 2020-03-31 | ₹182.24 | ₹2104.00 | x |
| 2021-03-31 | ₹234.16 | ₹2104.00 | x |
| 2022-03-31 | ₹275.62 | ₹2104.00 | x |
| 2023-03-31 | ₹158.37 | ₹2104.00 | x |
| 2024-03-31 | ₹184.34 | ₹2104.00 | x |
| 2025-03-31 | ₹216.33 | ₹2104.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently JB Chemicals & Pharmaceuticals Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 19.21%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 16.83%
- • Asset Turnover: 0.92x
- • Equity Multiplier: 1.24x
- Recent ROE (19.21%) is above the historical average (17.82%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 20.53% | 16.26% | 0.87x | 1.45x | ₹299.28 Million |
| 2006 | 21.26% | 15.08% | 0.92x | 1.53x | ₹371.99 Million |
| 2007 | 14.86% | 11.83% | 0.74x | 1.70x | ₹203.31 Million |
| 2008 | 10.00% | 8.06% | 0.76x | 1.64x | ₹179.40K |
| 2009 | 5.48% | 3.59% | 0.96x | 1.59x | ₹-211.79 Million |
| 2010 | 20.90% | 16.03% | 0.89x | 1.47x | ₹619.41 Million |
| 2011 | 20.15% | 16.55% | 0.84x | 1.45x | ₹701.69 Million |
| 2012 | 69.89% | 84.54% | 0.67x | 1.23x | ₹5.81 Billion |
| 2013 | 7.79% | 10.11% | 0.60x | 1.27x | ₹-225.83 Million |
| 2014 | 5.90% | 6.55% | 0.69x | 1.30x | ₹-427.85 Million |
| 2015 | 10.09% | 9.57% | 0.71x | 1.49x | ₹9.18 Million |
| 2016 | 14.80% | 13.86% | 0.75x | 1.42x | ₹525.07 Million |
| 2017 | 13.50% | 14.05% | 0.78x | 1.23x | ₹476.96 Million |
| 2018 | 9.60% | 9.99% | 0.78x | 1.22x | ₹-58.15 Million |
| 2019 | 13.07% | 12.01% | 0.90x | 1.21x | ₹454.54 Million |
| 2020 | 18.95% | 15.61% | 0.96x | 1.26x | ₹1.28 Billion |
| 2021 | 24.75% | 22.33% | 0.90x | 1.24x | ₹2.67 Billion |
| 2022 | 18.06% | 15.90% | 0.93x | 1.22x | ₹1.72 Billion |
| 2023 | 16.52% | 13.15% | 0.88x | 1.43x | ₹1.62 Billion |
| 2024 | 18.90% | 15.86% | 0.87x | 1.37x | ₹2.60 Billion |
| 2025 | 19.21% | 16.83% | 0.92x | 1.24x | ₹3.16 Billion |
Industry Comparison
This section compares JB Chemicals & Pharmaceuticals Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $12,445,167,922
- Average return on equity (ROE) among peers: 14.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| JB Chemicals & Pharmaceuticals Limited (JBCHEPHARM) | ₹38.06 Billion | 20.53% | 0.24x | $1.93 Billion |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $802.45 Million | 7.70% | 1.12x | $11.20 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.12 Billion | 12.32% | 2.74x | $149.72 Million |
| Abbott India Limited (ABBOTINDIA) | $42.33 Billion | 33.41% | 0.40x | $1.59 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $15.68 Billion | 32.33% | 0.16x | $1.46 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.83 Million |
| Albert David Limited (ALBERTDAVD) | $2.44 Billion | 9.06% | 0.40x | $15.85 Million |
| Alivus Life Sciences Limited (ALIVUS) | $28.17 Billion | 17.24% | 0.21x | $333.13 Million |
| Alkem Laboratories Limited (ALKEM) | $23.74 Billion | 20.90% | 0.71x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $56.73 Million | 0.53% | 2.47x | $5.55 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $2.91 Billion | 13.70% | 0.25x | $77.60 Million |